What was the primary purpose of the debt exchange?

The primary purpose was to refinance approximately $153 million of Vertex's existing convertible debt, extending the maturity date from 2007 to 2011 and adjusting the interest rate.

How will this exchange impact Vertex's financials?

The exchange will result in higher annual interest expense due to the increased coupon rate from 5% to 5.75%. However, it also extends the repayment period for this portion of the debt.

Are the new notes still convertible?

Yes, the newly issued notes are described as Convertible Senior Subordinated Notes due 2011, indicating they retain their convertibility feature, though the specific terms of conversion are not detailed in this filing.

What other information is provided in the filing?

The filing includes the Indenture governing the new notes, the Dealer Manager Agreement related to the exchange process, and a Resale Registration Rights Agreement, all of which are incorporated by reference as exhibits.

VRTX 8-K SEC Disclosure

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on February 23, 2004, detailing a significant debt exchange completed on February 13, 2004. The company successfully exchanged approximately $153 million of its 5% Convertible Subordinated Notes due 2007 for an equivalent principal amount of newly issued 5.75% Convertible Senior Subordinated Notes due 2011. This transaction effectively refinanced a portion of Vertex's outstanding debt, extending the maturity date and increasing the coupon rate on the convertible notes. Investors should note the change in terms, which may impact the company's interest expense and the conversion features of the debt. The filing also includes related documentation such as the Indenture, Dealer Manager Agreement, and Resale Registration Rights Agreement as exhibits.

Key Highlights

1Completed a debt exchange of approximately $153 million in principal amount of 5% Convertible Subordinated Notes due 2007.
2Issued new 5.75% Convertible Senior Subordinated Notes due 2011 in exchange for the existing notes.
3The exchange effectively refinanced existing debt and extended maturity to 2011.
4The new notes carry a higher interest rate of 5.75% compared to the previous 5%.
5The filing includes key legal documents related to the exchange as exhibits.

VERTEX PHARMACEUTICALS INC / MA 8-K Report (Feb 23, 2004)

Summary

Key Highlights

Frequently Asked Questions